72 related articles for article (PubMed ID: 7502054)
21. Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus.
Ensoli B; Cafaro A
AIDS Clin Rev; 2000-2001; ():23-61. PubMed ID: 10999215
[No Abstract] [Full Text] [Related]
22. [Live attenuated viruses: a new strategy for vaccination against AIDS].
Molina JM
Pathol Biol (Paris); 1993 Jun; 41(6):513-4. PubMed ID: 8247628
[No Abstract] [Full Text] [Related]
23. Will there be a live-attenuated HIV vaccine available for human safety trials by the year 2000? Interview by Gordon Nary.
Desrosiers RC
J Int Assoc Physicians AIDS Care; 1998 Nov; 4(11):22-3. PubMed ID: 11366120
[TBL] [Abstract][Full Text] [Related]
24. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
[TBL] [Abstract][Full Text] [Related]
25. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection.
Pope M; Haase AT
Nat Med; 2003 Jul; 9(7):847-52. PubMed ID: 12835704
[TBL] [Abstract][Full Text] [Related]
26. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.
Edghill-Smith Y; Venzon D; Karpova T; McNally J; Nacsa J; Tsai WP; Tryniszewska E; Moniuszko M; Manischewitz J; King LR; Snodgrass SJ; Parrish J; Markham P; Sowers M; Martin D; Lewis MG; Berzofsky JA; Belyakov IM; Moss B; Tartaglia J; Bray M; Hirsch V; Golding H; Franchini G
J Infect Dis; 2003 Oct; 188(8):1181-91. PubMed ID: 14551889
[TBL] [Abstract][Full Text] [Related]
27. Live attenuated AIDS vaccines: hazards and hopes.
Johnson RP
Nat Med; 1999 Feb; 5(2):154-5. PubMed ID: 9930861
[No Abstract] [Full Text] [Related]
28. SHIV transmission and susceptibility to re-exposure through social contact following vaccination with an HIV synthetic peptide-cocktail: a case study.
Hill LR; Nehete PN; Schapiro SJ; Nehete BP; Sastry KJ
J Med Primatol; 2004 Feb; 33(1):10-5. PubMed ID: 15061727
[TBL] [Abstract][Full Text] [Related]
29. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
30. HIV transmission: the genetic bottleneck. Newspaper Article.
Noble S
IAVI Rep; 2008; 12(6):4-8. PubMed ID: 20218017
[No Abstract] [Full Text] [Related]
31. AIDS vaccine development: let a thousand flowers bloom.
Oxford JS; Addawe M; Lambkin R
J Clin Pathol; 1998 Oct; 51(10):725-30. PubMed ID: 10023333
[No Abstract] [Full Text] [Related]
32. AIDS vaccine: new ideas from old approaches.
Beale AJ
J R Soc Med; 2003 Jul; 96(7):347-8. PubMed ID: 12835449
[No Abstract] [Full Text] [Related]
33. Attenuated retrovirus vaccines and AIDS.
Kestler HW; Jeang KT
Science; 1995 Nov; 270(5239):1219; author reply 1220-2. PubMed ID: 7502052
[No Abstract] [Full Text] [Related]
34. Feasibility of developing live attenuated HIV vaccines: conclusions and recommendations. World Health Organization Working Group.
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):221-2. PubMed ID: 8198875
[No Abstract] [Full Text] [Related]
35. Live attenuated HIV vaccines: a proposal for further research and development.
Mills J; Desrosiers R; Rud E; Almond N
AIDS Res Hum Retroviruses; 2000 Oct; 16(15):1453-61. PubMed ID: 11054258
[No Abstract] [Full Text] [Related]
36. HIV vaccines.
Ellenberg SS; Rida WN
Lancet; 1997 Feb; 349(9048):361. PubMed ID: 9024406
[No Abstract] [Full Text] [Related]
37. US and Thai researchers showed the world in 2009 that HIV can be prevented by vaccination.
Kher U
IAVI Rep; 2013; 17(3):2. PubMed ID: 24199316
[No Abstract] [Full Text] [Related]
38. Is population-level perversity a likely outcome of mass vaccination against HIV?
Bogaards JA; van Ballegooijen WM; Jan Weverling G; Boerlijst MC; Goudsmit J
Lancet Infect Dis; 2005 May; 5(5):254; author reply 255-6. PubMed ID: 15854875
[No Abstract] [Full Text] [Related]
39. Prevention: our major weapon against HIV infection and AIDS. Report on the Ninth International Conference on AIDS, Berlin, Germany, 6-11 June, 1993.
Lachat MF
Midwifery; 1993 Dec; 9(4):243-5. PubMed ID: 7904326
[No Abstract] [Full Text] [Related]
40. A piece of my mind. Vaccine, please.
Scurlock D
JAMA; 2010 Jul; 304(3):250-1. PubMed ID: 20639552
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
